Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Pattern-Similarity With 1998, Is Predicting A Pullback in the S&P 500

Our working hypothesis is that the dominant human emotion, fear leaves traces in the pricing history of the market which emerge as repetitive patterns . We search for these patterns and analyze the correlations between these patterns and market performance, in order to keep...
ANGtraders.com | March 7, 2019 |

NantKwest Shares Jump More than 50% Following JP Morgan Healthcare Conference Presentation

Shares of NantKwest Inc. spiked as much as 85% higher in mid-morning trading setting a new 52-week high price after the company reported a series of positive results at the 38th J.P. Morgan Healthcare Conference in San Francisco. The firm reported that complete responses were ...
Streetwise Reports | January 17, 2020 |

Feb 8th 2020, Silver Chartbook – The bigger picture

The bigger picture Silver prices are driven by several different factors, which are often opposing in effect. What is the bigger picture? There’s an inverse relationship between the strength of the US-Dollar and the price of silver. This is a c...
Korbinian Koller | February 10, 2020 |

Ecuador’s New Regulations on Scout Drilling, Lucky Minerals on Suture Fault Zone

New mining regulations issued by Government of Ecuador simplifies scout drilling/verification drilling process. Lucky Minerals Inc. (TSX-V: LKY) on Cu-Au porphyry system with overprinting gold system, linked to major suture fault. ” If ...
James O'Rourke | March 29, 2019 |

How to Unrig the Gold Market, According to GATA’s Chris Powell

In an earlier post, I gave you a sneak preview of my interview with Chris Powell, secretary/treasurer at Gold Anti-Trust Action Committee (GATA). For 20 years now, Chris and others at GATA have made it their mission to expose collusion by international financial institutions...
Frank Holmes | May 22, 2019 |

Are Investors Blind To The Equities Upside Super Cycle?

Our research team believes the upside pricing potential of the US market could be under-estimated by global traders and investors. We've been pouring over the charts and data trying to substantiate our hypothesis with our proprietary price modeling systems and technical analys...
Chris Vermeulen | March 27, 2019 |

Global breadth remains supportive for stocks

As the trade war impacts the U.S. economy, global breadth remains supportive for stocks. Today’s headlines: Global breadth Defensive stocks outperforming Imports and exports hit by trade war Mortgage Refinance Index spikes Will the S...
Troy Bombardia | June 13, 2019 |

Avadel Pharma Shares Up 30% Upon Acceleration of Phase 3 REST-ON Study

Avadel Pharmaceuticals' shares are trading 30% higher today on news that the FDA agreed to reduce the sample size required for its Phase 3 REST-ON study, accelerating its completion by year-end 2019. Dublin, Ireland-based Avadel Pharmaceuticals Plc (AVDL:NASDAQ) , wh...
Streetwise Reports | September 24, 2019 |

Phase 2 Data from Potential Multibagger Biopharma 'Checks All the Boxes'

The latest clinical trial results are dissected in a ROTH Capital Partners report. In a Sept. 26 research note, ROTH Capital Partners analyst Jerry Isaacson reported that AzurRx BioPharma Inc.'s (AZRX:NASDAQ) Phase 2 OPTION trial for lead candidate MS1819 in cystic ...
Streetwise Reports | October 1, 2019 |

Navidea Shares Jump 60% on Phase 2b Rheumatoid Arthritis Trial Results

Shares of Navidea Biopharmaceuticals traded 60% higher today on extremely high relative volume after the firm released data from its Phase 2b Rheumatoid Arthritis Tc 99m Tilmanocept Planar Imaging study. Developer of precision immunodiagnostic agents and immunotherape...
Streetwise Reports | October 30, 2019 |
1 2 3